Sana Biotechnology, Inc. (NASDAQ:SANA) Wells Fargo twentieth Annual Healthcare Convention 2025 September 4, 2025 8:00 AM EDT
Firm Contributors
Steven Harr – President, CEO & Director
Convention Name Contributors
Yanan Zhu – Wells Fargo Securities, LLC, Analysis Division
Presentation
Yanan Zhu
Senior Fairness Analyst
Nice. Thanks, everybody, for being right here. My title is Yanan Zhu. I am one of many biotech analysts right here at Wells Fargo. It’s my nice pleasure to be doing this hearth chat with Steve Harr, CEO of Sana Biotechnology. Steve, thanks a lot for being right here.
Steven Harr
President, CEO & Director
Thanks for having me, and I actually recognize Wells Fargo placing this collectively. And I am certain you recognize we’ll be making forward-looking statements throughout this time, and other people might want to check out our disclosures and danger components within the 10-Q. We spend a variety of time writing them. They’re often value studying.
Query-and-Reply Session
Yanan Zhu
Wells Fargo Securities, LLC, Analysis Division
Nice. Nice. Steve, maybe you might begin us off by offering an outline of the corporate and in addition evaluation the catalysts buyers ought to take note of within the subsequent 6 to 12 months.
Steven Harr
President, CEO & Director
Positive. I like the previous query. I will allow you to guys determine what the inventory catalysts are. I am fairly considerate on how we’re constructing the enterprise and perhaps how we take into consideration progress that we’re making and you then guys can determine what’s going to occur to the inventory value. A few issues that I will simply take a step again. We had been based with the concept that cell and gene remedy can be one of many extra vital transformations in drugs over the approaching many years. And there is nothing that we have seen over the previous couple of years, despite the fact that it has been an excellent difficult area
